GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » EBIT

Quanterix (Quanterix) EBIT : $-52.7 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Quanterix EBIT?

Quanterix's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-14.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-52.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Quanterix's annualized ROC % for the quarter that ended in Mar. 2024 was -59.89%. Quanterix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -85.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Quanterix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -14.15%.


Quanterix EBIT Historical Data

The historical data trend for Quanterix's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix EBIT Chart

Quanterix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only -41.60 -31.58 -58.59 -72.36 -48.16

Quanterix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.42 -9.56 -13.77 -15.38 -13.97

Competitive Comparison of Quanterix's EBIT

For the Medical Devices subindustry, Quanterix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quanterix's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quanterix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quanterix's EV-to-EBIT falls into.



Quanterix EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quanterix  (NAS:QTRX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Quanterix's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-55.864 * ( 1 - -2.65% )/( (92.598 + 98.893)/ 2 )
=-57.344396/95.7455
=-59.89 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=425.011 - 11.089 - ( 321.324 - max(0, 38.457 - 378.394+321.324))
=92.598

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=411.749 - 10.935 - ( 301.921 - max(0, 32.241 - 366.763+301.921))
=98.893

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Quanterix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-55.864/( ( (36.177 + max(22.854, 0)) + (35.24 + max(36.967, 0)) )/ 2 )
=-55.864/( ( 59.031 + 72.207 )/ 2 )
=-55.864/65.619
=-85.13 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(25.414 + 22.365 + 9.291) - (11.089 + 9.468 + 13.659)
=22.854

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(29.276 + 26.015 + 9.551) - (10.935 + 10.234 + 6.706)
=36.967

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Quanterix's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-52.677/372.282
=-14.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quanterix EBIT Related Terms

Thank you for viewing the detailed overview of Quanterix's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Quanterix (Quanterix) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlesex Turnpike, Billerica, MA, USA, 01821
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Executives
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly director C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram officer: Chief Financial Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser director 561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle officer: CFO and Treasurer C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue officer: President, Quanterix & Dx C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka director 2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
John J Fry officer: General Counsel & Secretary 8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky director, officer: EC, President & CEO 68 ELM STREET, HOPKINTON MA 01748
Karen Flynn director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy officer: SVP R&D and CTO C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon officer: Sr VP, Stgc Mrktg & Assay Tech 113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421